Newsroom
Category
March 18, 2022
Ruben A. Mesa, MD, FACP, professor of medicine and executive director of the Mays Cancer Center at UT Health San Antonio, testified on clinical trial diversity yesterday (March 17, 2022) before the House Committee on Energy and Commerce. The hearing was titled “The Future of Medicine: Legislation to Encourage Innovation and Improve Oversight.” Dr. Mesa […]
March 17, 2022
Cancer and virology researcher Reuben Harris, PhD, has been named chairman of the Department of Biochemistry and Structural Biology at UT Health San Antonio. The department is in the Joe R. and Teresa Lozano Long School of Medicine. Dr. Harris, a professor with tenure, will assume his duties effective April 11, 2022, announced Robert Hromas, […]
March 10, 2022
An internationally recognized physician-scientist of Mays Cancer Center at UT Health San Antonio, together with SignalRx Pharmaceuticals Inc., have secured two National Cancer Institute business grants to further develop drugs on a pathway to first-in-human cancer clinical trials. The clinical translational researcher, Daruka Mahadevan, MD, PhD, division chief of hematology and medical oncology at UT […]
March 3, 2022
The FDA has approved pacritinib for myelofibrosis patients with low platelet counts. Investigators at the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, played a lead role in gaining U.S. Food and Drug Administration approval of pacritinib to treat the chronic leukemia known as myelofibrosis. The FDA granted accelerated approval of the […]
March 2, 2022
Dr. Ruben Mesa, Mays Cancer Center, is quoted in this article. Read More
March 1, 2022
Dr. Ruben Mesa, executive director of the Mays Cancer Center, gives video comments about FDA approval of a new drug for a chronic leukemia. Watch Video